ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies (NCT06656494)

🧪 Interventions in This Study

• ICP-248 (DRUG)
• Azacitidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
• Yale University, Yale Cancer Center — New Haven, Connecticut
• H Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
• NYU Langone Health — New York, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Medical College of Wisconsin — Milwaukee, Wisconsin
• St Vincent's Hospital — Sydney, New South Wales
• Royal Perth Hospital — Perth, Western Australia
• Anhui Provincial Hospita — Hefei, Anhui
• Peking University People's Hospital — Beijing, Beijing Municipality
• The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong
• Nanfang Hospital Southern Medical University — Guangzhou, Guangdong
• Henan Cancer Hospital — Zhengzhou, Henan
• Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei
• The First Affiliated Hospital of Soochow University — Suzhou, Jiangsu
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
• The First Hospital of Jilin University — Changchun, Jilin
• Shengjing Hospital of China Medical University — Shengyang, Liaoning
• Sichuan Provincial People's Hospital — Chengdu, Sichuan
• Tianjin People's Hospital — Tianjin, Tianjin Municipality
• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang

📞 Contact the Study Coordinator

Phone: 010-66609745

Email: CO_HGRAC@innocarepharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myelogenous Leukemia

• Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia — Los Angeles, California
• Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients — Boston, Massachusetts
• DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission — Boston, Massachusetts
• Allo HSCT Using RIC and PTCy for Hematological Diseases — Minneapolis, Minnesota
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Cleveland, Ohio
• Cord Blood Transplantation in Children and Young Adults With Blood Cancer — New York, New York

Explore by condition: All Acute Myelogenous Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.